Abstract
Cutaneous melanoma is a significant oncological condition in countries with large Caucasian populations. Not only is there a rising incidence rate, but mortality rates have also increased in many countries (Jemal et al. 2008). As demonstrated from Cancer Registry Data in NSW Australia, the age standardized incidence has risen by 16% in males and 24% in females over the 10 years from 1996 to 2005. It accounts for almost 10% of malignancies, with an incidence of 59.8 new cases per 100,000 in males. One in 24 males and one in 33 females will develop a melanoma by age 75. Melanoma ranks as the 7th most common cause for cancer related mortality in males (Tracey et al. 2006).
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Andrews DW, Scott CB, Sperduto PW (2004) Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363:1665–1672
Ang KK, Peters LJ, Weber RS et al. (1994) Postoperative radiotherapy for cutaneous melanoma of the head and neck region. Int J Radiat Oncol Biol Phys 30:795–798
Balch CM, Soong SJ, Smith T et al. (2001a) Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1–4 mm melanomas. Ann Surg Oncol 8:101–108
Balch CM, Soong SJ, Gershenwald JE et al. (2001b) Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19:3622–3634
Ballo MT, Bonnen MD, Garden AS et al. (2003) Adjuvant irradiation for cervical lymph node metastases from melanoma. Cancer 97:1789–1796
Blessing K, Sanders DS, Grant JJ (1998) Comparison of immunohistochemical staining of the novel antibody melan-A with S100 protein and HMB-45 in malignant melanoma and melanoma variants. Histopathology 32:139–146
Bliss JM, Ford D, Swerdlow AJ et al. (1995) Risk of cutaneous melanoma associated with pigmentation characteristics and freckling: systematic overview of 10 case-control studies. The International Melanoma Analysis Group (IMAGE). Int J Cancer 62:367–376
Bonnen MD, Ballo MT, Myers JN et al. (2004) Elective radiotherapy provides regional control for patients with cutaneous melanoma of the head and neck. Cancer 100:383–389
Bub JL, Berg D, Slee A, Odland PB (2004) Management of lentigo maligna and lentigo maligna melanoma with staged excision: a 5-year follow-up. Arch Dermatol. May 140:552–558
Buchsbaum JC, Suh JH, Lee SY et al. (2002) Survival by radiation therapy oncology group recursive partitioning analysis class and treatment modality in patients with brain metastases from malignant melanoma: a retrospective study. Cancer 94:2265–2272
Burmeister BH, Smithers BM, Davis S et al. (2002) Radiation therapy following nodal surgery for melanoma: an analysis of late toxicity. ANZ J Surg 72:344–348
Burmeister BH, Mark Smithers B, Burmeister E et al. (2006) A prospective phase II study of adjuvant postoperative radiation therapy following nodal surgery in malignant melanoma-Trans Tasman Radiation Oncology Group (TROG) Study 96.06. Radiother Oncol 81:136–142
Buzaid AC, Tinoco L, Ross MI, Legha SS, Benjamin RS (1995) Role of computed tomography in the staging of patients with local-regional metastases of melanoma. J Clin Oncol13:2104–2108.
Calabro A, Singletary SE, Balch CM (1989) Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases. Arch Surg 124:1051–1055
Cascinelli N, Belli F, Santinami M et al. (2000) Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. Ann Surg Oncol 7:469–474
Chapman PB (2007) Melanoma vaccines. Semin Oncol 34:516–523
Constantinidou A, Hofman M, O’Doherty M et al. (2008) Routine positron emission tomography and positron emission tomography/computed tomography in melanoma staging with positive sentinel node biopsy is of limited benefit. Melanoma Res 18:56–60
Cornett WR, McCall LM, Petersen RP et al. (2006) Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol 24:4196–4201
Eigentler TK, Caroli UM, Radny P, Garbe C (2003) Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 4:748–759
Essner R, Lee JH, Wanek LA et al. (2004) Contemporary surgical treatment of advanced-stage melanoma. Arch Surg 139:961–966
Fader DJ, Wise CG, Normolle DP, Johnson TM (1998) The multidisciplinary melanoma clinic: a cost outcomes analysis of specialty care. J Am Acad Dermatol 38(5 Pt 1):742–751
Farshad A, Burg G, Panizzon R, Dummer R (2002) A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays. Br J Dermatol 146:1042–1046
Fife KM, Colman MH, Stevens GN et al. (2004) Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 22:1293–300
Fife KM, Colman MH, Stevens GN et al. (2004) Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 22:1293–1300
Francken AB, Bastiaannet E, Hoekstra HJ (2005) Follow-up in patients with localised primary cutaneous melanoma. Lancet Oncol 6:608–621
Francken AB, Shaw HM, Accortt NA et al. (2007) Detection of first relapse in cutaneous melanoma patients: implications for the formulation of evidence-based follow-up guidelines. Ann Surg Oncol 14:1924–1933
Goldstein A, Chan M, Harland M et al. (2007) Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet 44:99–106
Greene F, Page D, Fleming I et al. (2002) AJCC Cancer Staging Manual, 6th edn. Springer, Berlin Heidelberg New York
Hazan C, Dusza SW, Delgado R et al. (2008) Staged excision for lentigo maligna and lentigo maligna melanoma: a retrospective analysis of 117 cases. J Am Acad Dermatol 58:142–148
Hazard LJ, Sause WT, Noyes RD (2002) Combined adjuvant radiation and interferon-alpha 2B therapy in high-risk melanoma patients: the potential for increased radiation toxicity. Int J Radiat Oncol Biol Phys 52:796–800
Huilgol SC, Selva D, Chen C et al. (2004) Surgical margins for lentigo maligna and lentigo maligna melanoma: the technique of mapped serial excision. Arch Dermatol 140:1087–1092
Jemal A, Siegel R, Ward E et al. (2008) Cancer Statistics 2008. CA Cancer J Clin 58:71–96
Jost LM, Jelic S, Purkalne G (2005) ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of cutaneous malignant melanoma. Ann Oncol 16[Suppl 1]:i66–i68
Khayat D, Rixe O, Martin G et al. (2003) Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). Cancer 97:1941–1946
Kiebert GM, Jonas DL, Middleton MR (2003) Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine. Cancer Invest 21:821–829
Kirkwood JM, Strawderman MH, Ernstoff MS et al. (1996) Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14:7–17
Kirkwood JM, Ibrahim JG, Sondak VK et al. (2000) High-and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 18:2444–2458
Kirkwood JM, Bender C, Agarwala S et al. (2002) Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol 20:3703–3718
Manon R, O’Neill A, Knisely J et al. (2005) Phase II trial of radiosurgery for one to three newly diagnosed brain metastases from renal cell carcinoma, melanoma, and sarcoma: an Eastern Cooperative Oncology Group study (E 6397). J Clin Oncol 23:8870–8876
McCarthy WH, Shaw HM, Thompson JF et al (1988) Time and frequency of recurrence of cutaneous stage I malignant melanoma with guidelines for follow up study. Surg Gynecol Obstet 166:497–502
Meisenberg BR, Ross M, Vredenburgh JJ et al. (1993) Randomized trial of high-dose chemotherapy with autologous bone marrow support as adjuvant therapy for highrisk, multi-node-positive malignant melanoma. J Natl Cancer Inst 85:1080–1085
Mendenhall WM, Amdur RJ, Grobmyer SR et al. (2008) Adjuvant radiotherapy for cutaneous melanoma. Cancer 112:1189–1196
Middleton MR, Grob JJ, Aaronson N et al. (2000) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18:158–166
Miranda EP (2006) Utility of computed tomography and magnetic resonance imaging staging before completion lymphadenectomy in sentinel lymph node-positive melanoma. J Clin Oncol 24:5178
Morton D, Eilber FR, Malmgren RA, Wood WC (1970) Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 68:158–163
Morton DL, Thompson JF, Cochran AJ et al. (2006) Sentinelnode biopsy or nodal observation in melanoma. N Engl J Med 355:1307–1317
Mosca PJ, Teicher E, Nair SP, Pockaj BA (2008) Can surgeons improve survival in stage IV melanoma? J Surg Oncol [Epub ahead of print]
Olivier KR, Schild SE, Morris CG et al. (2007) A higher radiotherapy dose is associated with more durable palliation and longer survival in patients with metastatic melanoma. Cancer 110:1791–1795
Overgaard J, Overgaard M, Hansen PV, von der Maase H (1986) Some factors of importance in the radiation treatment of malignant melanoma. Radiother Oncol 5:183–192
Petrella T, Quirt I, Verma S et al. (2007) Single-agent interleukin-2 in the treatment of metastatic melanoma. Curr Oncol 14:21–26
Posther KE, Selim MA, Mosca PJ et al. (2006) Histopathologic characteristics, recurrence patterns, and survival of 129 patients with desmoplastic melanoma. Ann Surg Oncol 13:728–739
Quinn MJ, Crotty KA, Thompson JF et al. (1998) Desmoplastic and desmoplastic neurotropic melanoma: experience with 280 patients. Cancer 83:1128–1135
Reinhardt MJ, Joe AY, Jaeger U et al. (2006) Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N-and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol 24:1178–1187
Sasse AD, Sasse EC, Clark LG et al. (2007) Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. Cochrane Database Syst Rev. Jan 24; (1):CD005413
Sause WT, Cooper JS, Rush S et al. (1991) Fraction size in external beam radiation therapy in the treatment of melanoma. Int J Radiat Oncol Biol Phys 20:429–32
Seegenschmiedt MH, Keilholz L, Altendorf-Hofmann A et al. (1999) Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience. Int J Radiat Oncol Biol Phys 44:607–618
Schmalbach CE, Nussenbaum B, Rees RS et al. (2003) Reliability of sentinel lymph node mapping with biopsy for head and neck cutaneous melanoma. Arch Otolaryngol Head Neck Surg 129:61–65
Stevens G, Thompson JF, Firth I, O’Brien CJ, McCarthy WH, Quinn MJ (2000) Locally advanced melanoma: results of postoperative hypofractionated radiation therapy. Cancer 88:88–94
Stevens G, McKay M (2006) Dispelling the myths surrounding radiotherapy for treatment of cutaneous melanoma. Lancet Oncol 7:575–583
Sze WM, Shelley M, Held I, Mason M (2004) Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy — a systematic review of the randomised trials. Cochrane Database Syst Rev. (2):CD004721
Thomas JM, Clark MA (2004) Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma. Eur J Surg Oncol 30:686–691
Tracey EA, Chen S, Baker D, Bishop J, Jelfs P (2006) Cancer in New South Wales: incidence and mortality 2004. Cancer Institute NSW, Sydney, November
Tsao H, Atkins M, Sober A (2004) Management of cutaneous melanoma. N Engl J Med 351:998–1012
Wheatley K, Ives N, Hancock B et al. (2003) Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 29:241–252
Wu JS, Wong R, Johnston M et al. (2003) Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys 55:594–605
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Back, M.F. (2008). Cutaneous Malignant Melanoma. In: Lu, J.J., Brady, L.W. (eds) Radiation Oncology. Medical Radiology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-77385-6_35
Download citation
DOI: https://doi.org/10.1007/978-3-540-77385-6_35
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-77384-9
Online ISBN: 978-3-540-77385-6
eBook Packages: MedicineMedicine (R0)